Acorah Software Products - Accounts Production 19.3.600 false true true 31 August 2024 1 September 2023 false 1 September 2024 31 August 2025 31 August 2025 13564111 Mr Jogchum Brinksma Dr David Fairen-Jimenez Ms Lluna Gallego Segrelles iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 13564111 frs-core:CurrentFinancialInstruments frs-core:WithinOneYear 2025-08-31 13564111 2024-08-31 13564111 2025-08-31 13564111 2024-09-01 2025-08-31 13564111 frs-core:CurrentFinancialInstruments 2025-08-31 13564111 frs-core:ComputerEquipment 2025-08-31 13564111 frs-core:ComputerEquipment 2024-09-01 2025-08-31 13564111 frs-core:ComputerEquipment 2024-08-31 13564111 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-09-01 2025-08-31 13564111 frs-core:OtherResidualIntangibleAssets 2025-08-31 13564111 frs-core:OtherResidualIntangibleAssets 2024-09-01 2025-08-31 13564111 frs-core:OtherResidualIntangibleAssets 2024-08-31 13564111 frs-core:ShareCapital 2025-08-31 13564111 frs-core:RetainedEarningsAccumulatedLosses 2025-08-31 13564111 frs-bus:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 13564111 frs-bus:FilletedAccounts 2024-09-01 2025-08-31 13564111 frs-bus:SmallEntities 2024-09-01 2025-08-31 13564111 frs-bus:AuditExempt-NoAccountantsReport 2024-09-01 2025-08-31 13564111 frs-bus:SmallCompaniesRegimeForAccounts 2024-09-01 2025-08-31 13564111 frs-bus:OrdinaryShareClass1 2024-09-01 2025-08-31 13564111 frs-bus:OrdinaryShareClass1 2025-08-31 13564111 frs-bus:Director1 2024-09-01 2025-08-31 13564111 frs-bus:Director2 2024-09-01 2025-08-31 13564111 frs-bus:Director3 2024-09-01 2025-08-31 13564111 frs-countries:EnglandWales 2024-09-01 2025-08-31 13564111 frs-core:CurrentFinancialInstruments frs-core:WithinOneYear 2024-08-31 13564111 2023-08-31 13564111 2024-08-31 13564111 2023-09-01 2024-08-31 13564111 frs-core:CurrentFinancialInstruments 2024-08-31 13564111 frs-core:ShareCapital 2024-08-31 13564111 frs-core:RetainedEarningsAccumulatedLosses 2024-08-31 13564111 frs-bus:OrdinaryShareClass1 2023-09-01 2024-08-31
Registered number: 13564111
Vector Bioscience Cambridge Ltd
Unaudited Financial Statements
For The Year Ended 31 August 2025
Wilson Partners Ltd
Ketton Suite The King Centre, Main Road
Barleythorpe
Oakham
LE15 7WD
Vector Bioscience Cambridge Ltd
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—6

Page 1
Vector Bioscience Cambridge Ltd
Balance Sheet
As At 31 August 2025
Balance Sheet
Registered number: 13564111

| 2025 | 2024 as restated
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Intangible Assets | 4 |  | 22,988 |  | 25,748
Tangible Assets | 5 |  | 3,599 |  | 6,483
|  |  | 26,587 |  | 32,231
CURRENT ASSETS
Debtors | 6 | 283,472 |  | 171,269 |
Cash at bank and in hand |  | 264,861 |  | 213,083 |
|  | 548,333 |  | 384,352 |
Creditors: Amounts Falling Due Within One Year | 7 | (320,392 ) |  | (321,319 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 227,941 |  | 63,033
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 254,528 |  | 95,264
NET ASSETS |  |  | 254,528 |  | 95,264
CAPITAL AND RESERVES
Called up share capital | 9 |  | 106 |  | 106
Profit and Loss Account |  |  | 254,422 |  | 95,158
SHAREHOLDERS' FUNDS |  |  | 254,528 |  | 95,264

Page 1
Page 2
Vector Bioscience Cambridge Ltd
Balance Sheet (continued)
As At 31 August 2025
For the year ending 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Ms Lluna Gallego Segrelles Director
20 August 2026

The notes on pages 3 to 6 form part of these financial statements.
Page 2
Page 3
Vector Bioscience Cambridge Ltd
Notes to the Financial Statements
For The Year Ended 31 August 2025
Notes to the Financial Statements
1. General Information
Vector Bioscience Cambridge Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 13564111 . The registered office is 20-22 Wenlock Road, London, N1 7GU.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
2.2. Going Concern Disclosure
The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern. Therefore the financial statements have been prepared on a going concern basis which assumes the Company will continue in operational existence for the foreseeable future.
The Company is involved in research and development activities and is working towards achieving a sustainable revenue generating activity. The directors have considered the basis of the financial statements and are satisfied that a combination of business growth and further investment commitments will enable the Company to meet its liabilities as they fall due.
2.3. Intangible Fixed Assets and Amortisation - Other Intangible
Other intangible assets include Patents. It is amortised to the profit and loss account over its estimated economic life of 10 years.
2.4. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer Equipment | Straight line over 3 years

2.5. Cash and Cash Equivalents
Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks, other short-term highly liquid investments that mature in no more than three months from the date of acquisition and are readily convertible to a known amount of cash with insignificant risk of change in value, and bank overdrafts.
2.6. Financial Instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Basic financial assets
Basic financial assets, which include debtors and bank balances, are measured at transaction price including transaction costs.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, are recognised at transaction price including transaction costs.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities.
Page 3
Page 4
Vector Bioscience Cambridge Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 August 2025
2.7. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the profit / loss before taxation.
2.8. Taxation
Tax is recognised in profit or loss except that a charge is attributable to an item of income and expense recognised as other comphrehensive income or to an item recognised directly in equity is also recognised in other comphrehensive income or directly in equity respectively.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the company operates and generates income.
2.9. Pensions
The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.
2.10. Government Grant
Government grants are recognised in the profit and loss account in an appropriate manner that matches them with the expenditure towards which they are intended to contribute.
Grants for immediate financial support or to cover costs already incurred are recognised immediately in the profit and loss account. Grants towards general activities of the entity over a specific period are recognised in the profit and loss account over that period.
Grants towards fixed assets are recognised over the expected useful lives of the related assets and are treated as deferred income and released to the profit and loss account over the useful life of the asset concerned.
All grants in the profit and loss account are recognised when all conditions for receipt have been complied with.
2.11. Research and Development
In the research phase of an internal project, it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.
2.12. Convertible Debt
Compound financial instruments issued by the Company comprise convertible loan notes that can be converted to share capital at the option of the holder. The interest on the loan notes is compounding annually and as such the number of shares to be issued will vary with changes in the fair value.
Due to the varying number of shares to be issued the loan notes are treated as liabilities and not split between equity and liabilities. The liability is initially and subsequently measured at fair value, with the fair value movements recognised in the Statement of Comprehensive Income.
Transaction costs that relate to the issue of the instrument are expensed to the Statement of Comprehensive Income.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 9 (2024: 6)
9 6
Page 4
Page 5
Vector Bioscience Cambridge Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 August 2025
4. Intangible Assets

| Other - Patents
--- | ---
| £
Cost
As at 1 September 2024 | 27,603
As at 31 August 2025 | 27,603
Amortisation
As at 1 September 2024 | 1,855
Provided during the period | 2,760
As at 31 August 2025 | 4,615
Net Book Value
As at 31 August 2025 | 22,988
As at 1 September 2024 | 25,748

5. Tangible Assets

| Computer Equipment
--- | ---
| £
Cost
As at 1 September 2024 | 8,652
As at 31 August 2025 | 8,652
Depreciation
As at 1 September 2024 | 2,169
Provided during the period | 2,884
As at 31 August 2025 | 5,053
Net Book Value
As at 31 August 2025 | 3,599
As at 1 September 2024 | 6,483

6. Debtors

| 2025 |  | 2024 as restated
--- | --- | --- | ---
| £ |  | £
Due within one year
Prepayments and accrued income | 150,229 |  | 112,437
Other debtors | 100 |  | 1,140
Corporation tax recoverable | 124,066 |  | 44,067
VAT | 9,077 |  | 13,625
| 283,472 |  | 171,269

Page 5
Page 6
Vector Bioscience Cambridge Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 August 2025
7. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024 as restated
--- | --- | --- | ---
| £ |  | £
Trade creditors | 36,592 |  | 62,854
Convertible loans | 261,787 |  | 241,844
Other taxes and social security | 11,215 |  | 11,807
Other creditors | 2,953 |  | 1,813
Accruals and deferred income | 7,845 |  | 3,001
| 320,392 |  | 321,319

8. Loans
An analysis of the maturity of loans is given below:

| 2025 |  | 2024 as restated
--- | --- | --- | ---
| £ |  | £
Amounts falling due within one year or on demand:
Other loans | 261,787 |  | 241,844

9. Share Capital

| 2025 |  | 2024 as restated
--- | --- | --- | ---
Allotted, called up and fully paid | £ |  | £
1,063,829 Ordinary Shares of £ 0.0001 each | 106 |  | 106

Page 6